Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?

Aims  We compared the immune response evaluation criteria in solid tumors (iRECIST) with immune adaptive positron emission tomography response criteria in solid tumors (imPERCIST) in lung cancer patients treated with nivolumab. Materials and Methods  Twenty lung cancer patients underwent fluorodeoxy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Manoj, Choudhury, Partha S., Jain, Parveen, Sharma, Manish, Koyyala, Venkata P. B., Goyal, Sumit, Agarwal, Chaturbhuj, Jajodia, Ankush, Pasricha, Sunil, Sharma, Anurag, Batra, Ullas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056126/
https://www.ncbi.nlm.nih.gov/pubmed/35502277
http://dx.doi.org/10.1055/s-0042-1744201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056126/
https://www.ncbi.nlm.nih.gov/pubmed/35502277
http://dx.doi.org/10.1055/s-0042-1744201

Ejemplares similares